TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20186975
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/day + Depression Care Management (DCM) + Interpersonal Psychotherapy (IPT) for 16 weekly sessions
Study: 20186975
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/day + Depression Care Management (DCM) without IPT
Study: 16253070
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of norfloxacin
Study: 12693324
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with Praziquantel (25-50 mg/kg for 14 days)
Study: 7588990
Drug: Intranasal Apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Apomorphine
Study: 7588990
Drug: Subcutaneous Apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Apomorphine
Study: 6958479
Drug: 4 divided
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 divided doses of BDP
Study: 6958479
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of BDP
Study: 21548919
Drug: Family-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive behavioral multidisciplinary lifestyle treatment
Study: 16682575
Drug: Electronic medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic medical record alerts for coprescription of warfarin and interacting medications (acetaminophen, nonsteroidal anti‐inflammatory medications, fluconazole, metronidazole, sulfamethoxazole)
Study: 15173406
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention (weekly home visits from birth to 8 weeks and from 7 to 24 months)
Study: 8737627
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (0.125 mg and 0.250 mg brotizolam)
Study: 1560699
Drug: Topical 40%
Normalized name: urea topical 40% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 40% idoxuridine in dimethyl sulfoxide (IDU)
Study: 3840882
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide (2 mg/kg)
Study: 3840882
Drug: Inhaled atropine
Normalized name: atropine sulfate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled atropine sulfate (0.05 mg/kg)
Study: 3840882
Drug: Inhaled isoproterenol
Normalized name: isoproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isoproterenol (0.2 cc, 1:200)
Study: 23075634
Drug: Alfentanil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil and morphine (Group AM)
Study: 17713162
Drug: TMC125 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC125 100 mg twice daily coadministered with DRV/r 600/100 mg twice daily
Study: 17713162
Drug: TMC125 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC125 200 mg twice daily coadministered with DRV/r 600/100 mg twice daily
Study: 17713162
Drug: DRV/r 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r 600/100 mg twice daily
Study: 15053373
Drug: Salbutamol alone
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol alone (0.03 ml/kg/dose)
Study: 15053373
Drug: Combined nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nebulization of Salbutamol (0.03 ml/kg/dose) and Ipratropium bromide (250 microgm/dose for three doses)
Study: 11575732
Drug: Treatment algorithms
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment algorithms for treatment-resistant depression
Study: 11575732
Drug: Texas Medication
Normalized name: influenza A virus A/Texas/50/2012 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Texas Medication Algorithm Project
Study: 11575732
Drug: Sequenced Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequenced Treatment Alternatives to Relieve Depression
Study: 9337491
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment package including cognitive correction, problem-solving training, social skills training, and relapse prevention
Study: 3035003
Drug: Anti-D immunoglobulin
Normalized name: Anti-D immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-D immunoglobulin injections at 28th and 34th weeks of pregnancy
Study: 3035003
Drug: Antepartum treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antepartum treatment
Study: 25596910
Drug: CONSORT dosing
Normalized name: AVOBENZONE 28.5 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTINOXATE 70 mg in 1 mL / OCTISALATE 30 mg in 1 mL / OCTOCRYLENE 90 mg in 1 mL TOPICAL CREAM [Pur Confort SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONSORT dosing (follitropin alfa starting dose determined by the CONSORT calculator)
Study: 25596910
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (150 IU of follitropin alfa)
Study: 21955647
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg genistein
Study: 21955647
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pure S-(−)equol
Study: 21955647
Drug: Soy infant
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy infant formula and soy germ isoflavone supplement
Study: 9446300
Drug: Infrared pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared pulsed laser therapy
Study: 1526696
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg and 20 mg
Study: 3886706
Drug: tolmetin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolmetin 1,200 mg/d for three weeks
Study: 25517279
Drug: Grape powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape powder (500 mg of polyphenols/day)
Study: 14529097
Drug: Montelukast (5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5-mg chewable tablet once daily)
Study: 14529097
Drug: Cromolyn (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (two puffs 4 times daily)
Study: 10634360
Drug: Testosterone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (300 mg, im, every 3 weeks)
Study: 10634360
Drug: NRTI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI treatment without protease inhibitor
Study: 10634360
Drug: NRTI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI treatment with protease inhibitor
Study: 9336129
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy with 60 Gy at 2.0 Gy per day (STD RT)
Study: 9336129
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin 100 mg/m2 days 1 and 29 with vinblastine 5 mg/m2 weekly for 5 weeks followed by 60 Gy at 2.0 Gy per day (CT + RT)
Study: 9336129
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy with 69.6 Gy at 1.2 Gy b.i.d. (HFX RT)
Study: 8441078
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tests (palpation or percussion)
Study: 2876325
Drug: Pneumococcal capsular
Normalized name: pneumococcal capsular polysaccharide type 1 vacc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal capsular polysaccharide vaccines
Study: 24218527
Drug: IFNB1b 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNB1b 250 μg subcutaneously every other day
Study: 22354108
Drug: Manual-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-assisted therapy (MAT)
Study: 18208849
Drug: Perfusion-cardiac magnetic
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion-cardiac magnetic resonance (perfusion-CMR) at a dose of 0.1 mmol/kg Gd-DTPA-BMA
Study: 15931612
Drug: Beef supplementation
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef supplementation (0.6 g-protein/kg per day)
Study: 12839376
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg/Kg/day; Group A, n = 12)
Study: 12839376
Drug: Sulfasalazine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (6 g/day; Group B, n = 13)
Study: 7473798
Drug: TRH (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (0.2 mg/kg intravenous bolus followed by 0.2 mg/kg/h infusion over 6 h)
Study: 2075851
Drug: High-dose addicts
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose addicts
Study: 2075851
Drug: Low-dose addicts
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose addicts
Study: 7053242
Drug: Ceftriaxone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 150 mg
Study: 7053242
Drug: Ceftriaxone 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1500 mg
Study: 6368591
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chenodiol (750 mg/d)
Study: 6368591
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose chenodiol (375 mg/d)
Study: 20804443
Drug: Technosphere Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technosphere Insulin (TI), single 30-U dose
Study: 18754845
Drug: Pre-HD folic
Normalized name: Pre Folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-HD folic acid (5 mg) administration
Study: 18754845
Drug: Intra-HD folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-HD folic acid (5 mg) administration
Study: 12876164
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term antibiotics
Study: 12876164
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (surgery and antibiotics)
Study: 1342209
Drug: Nitrendipine plus
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine plus ranitidine (300 mg, 150 mg twice a day)
Study: 3859359
Drug: CRT +
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRT + ITC (induction intrathecal chemotherapy and cranial irradiation plus maintenance ITC)
Study: 3859359
Drug: CSpRT (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSpRT (induction intrathecal chemotherapy and craniospinal irradiation with no maintenance ITC)
Study: 26824884
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily hydromorphone (HOD)
Study: 26824884
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily hydromorphone (HTD)
Study: 24850606
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg with UDCA
Study: 20669672
Drug: Tetramethylpyrazine (TMP)
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine (TMP) 240 mg/d added to conventional treatment for 10-14 days
Study: 20669672
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Piperacillin, Levofloxacin, Ambroxol, Doxofylline)
Study: 18510632
Drug: Alemtuzumab induction
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab induction followed by delayed tacrolimus monotherapy
Study: 18510632
Drug: Tacrolimus in
Normalized name: tacrolimus Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus in combination with mycophenolate mofetil and steroids
Study: 1478392
Drug: Aerobic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training program (thrice weekly for 8 weeks, starting at 40% of maximal oxygen uptake)
Study: 28811107
Drug: Intraoperative periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative periarticular injection with added morphine (0.1 mg/kg)
Study: 28811107
Drug: Intraoperative periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative periarticular injection without added morphine
Study: 8844450
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day for 16 days
Study: 1614087
Drug: 0.1% dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dexamethasone and antibiotics (first trial)
Study: 1614087
Drug: Antibiotics without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics without steroids (first trial)
Study: 1614087
Drug: 0.1% dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dexamethasone 4x daily (second trial)
Study: 1614087
Drug: 0.1% dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dexamethasone 4x daily for 5 days, then 1x daily (second trial)
Study: 1614087
Drug: 0.1% dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dexamethasone 1x daily (second trial)
Study: 30325583
Drug: Sarpogrelate 100-mg
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate 100-mg tablets under fasting conditions
Study: 30325583
Drug: Sarpogrelate 100-mg
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate 100-mg tablets under fed conditions
Study: 29247820
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (various agents and techniques)
Study: 29247820
Drug: Different anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different anesthetic techniques and drug subgroups
Study: 26429522
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg for 1 week
Study: 23052890
Drug: Therapeutic hypothermia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic hypothermia (TH) with an individual target range temperature between 34 and 35 °C administered for 24 hours
Study: 19914974
Drug: H(2) antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H(2) antagonists
Study: 17391558
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (6 g/d; about 2 g n-3 PUFA; 1.6 g DHA/d)
Study: 17391558
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (6 g/d, placebo)
Study: 17391558
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of moderate exercise and fish-oil supplementation
Study: 17391558
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and oil combination
Study: 15467102
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g x d(-1) Cr + 140 g x d(-1) glucose polymer)
Study: 15467102
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (responders with increased intramuscular Cr levels)
Study: 2253907
Drug: Famotidine infusion
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine infusion after 10 mg bolus
Study: 2253907
Drug: Famotidine infusion
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine infusion alone
Study: 31944250
Drug: Parent-administered exercise
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered exercise program (10 minutes twice a day for 3 weeks)
Study: 31944250
Drug: Parent-administered exercise
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered exercise program
Study: 30958348
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU intranasal insulin
Study: 23907764
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU intranasal insulin
Study: 24393856
Drug: Colorectal cancer-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorectal cancer-specific peptide vaccines (RNF43, TOMM34) with uracil/tegafur (UFT) + Leucovorin (LV)
Study: 24393856
Drug: Colorectal cancer-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorectal cancer-specific peptide vaccines (RNF43, TOMM34)
Study: 24393856
Drug: Vaccines against
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccines against multiple peptides (RNF43, TOMM34, FOXM1, MELK, HJURP, VEGFR1, VEGFR2)
Study: 21765371
Drug: Intravitreal diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal diclofenac (500 μg/0.1 mL)
Study: 21765371
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (4 mg/0.1 mL)
Study: 16671073
Drug: Bilateral subthalamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subthalamic nucleus deep brain stimulation (B‐STN DBS) plus medication
Study: 31802059
Drug: EVOO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVOO therapy
Study: 31802059
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (MCI without therapy)
Study: 24401516
Drug: Ventralex Hernia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventralex Hernia Patch (Bard USA)
Study: 12231575
Drug: AHA diet
Normalized name: AHA
DrugBank: Acetohydroxamic acid (DB00551)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AHA diet + simvastatin (20 mg daily)
Study: 31418121
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g rice with 4 g dried wakame
Study: 31418121
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g rice
Study: 21329988
Drug: Fluoxetine 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20mg/day plus celecoxib 400mg/day (200mg BID)
Study: 21329988
Drug: Fluoxetine 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20mg/day plus placebo
Study: 18789466
Drug: Anti-Giardia and
Normalized name: Giardia lamblia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Giardia and anthelminthic treatment
Study: 18789466
Drug: Anti-Giardia treatment
Normalized name: Giardia lamblia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Giardia treatment only
Study: 17721622
Drug: tinzaparin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: tinzaparin at 175 IU/kg, subcutaneous once daily, along with supportive care including morphine analgesia
Study: 15487811
Drug: Nisolone (test)
Normalized name: triamcinolone diacetate Injectable Suspension [Cinolone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisolone (test) tablets
Study: 15487811
Drug: Delta‐Cortef (reference)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta‐Cortef (reference) tablets
Study: 7923797
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose transdermal estrogen (Estraderm TTS 25 micrograms) + oral progestogen (Duphaston 10 mg, 10 days every month) + daily exercise (walking for 1 hour)
Study: 3301517
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg isosorbide dinitrate
Study: 28668524
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg/h)
Study: 27453154
Drug: Biofeedback software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback software on a novel tablet computer platform
Study: 26147154
Drug: OBV/PTV/r (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBV/PTV/r (25 mg/150 mg/100 mg) for 12 weeks (group A)
Study: 12809957
Drug: Cyclobenzaprine 5
Normalized name: cyclobenzaprine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 5 mg TID
Study: 12809957
Drug: Cyclobenzaprine 10
Normalized name: cyclobenzaprine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 10 mg TID
Study: 12809957
Drug: Cyclobenzaprine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 2.5 mg TID
Study: 10768448
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with progenitor-cell rescue
Study: 9275441
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of oxytocin (control group)
Study: 6378245
Drug: Diluted and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted and undiluted topical corticosteroid preparations
Study: 27314121
Drug: Roughened implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roughened implants
Study: 21904901
Drug: lamotrigine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamotrigine (target dose 400 mg/day)
Study: 17440020
Drug: Monofluorophosphate (MFP)
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monofluorophosphate (MFP) 20 mg/d
Study: 11589718
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic (LD; bumetanide)
Study: 11589718
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic (TD; bendroflumethiazide)